Heart Failure Risk Reduction in Diabetes: What the Practicing Endocrinologist Should Know

The goals of this program are to improve endocrinologists’ and other clinicians’ understanding and competence in leveraging the cardioprotective effects of SGLT2 inhibitors to reduce heart failure risk in patients with type 2 diabetes.

Target Audience

This activity is intended for endocrinologists, cardiologists, internists, primary care physicians, advanced practice providers, and other healthcare professionals who care for individuals with diabetes who are at risk for HF.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the pathologic mechanisms by which diabetes can lead to the development of HF
  • Characterize HF outcomes from CVOTs of SGLT2 inhibitors in patients with T2D
  • Describe strategies to foster collaboration between endocrinologists and cardiologists to optimize care of patients with T2D and HF

Additional Information

Target Audience: 
Physician-in-practice
Fellow
Resident
Clinical researcher
Scientific researcher
Educator/Teacher
Pharmacist
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Other
Competency Area: 
Medical Knowledge
Topic Area: 
Diabetes and Glucose Metabolism
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Level 4 (Learning: Competence (Shows How))
Activity summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation
Course opens: 
06/21/2021
Course expires: 
06/30/2022
Rating: 
0

Agenda

  • Heart Failure in Type 2 Diabetes: Overview of the Problem
  • SGLT2 Inhibition in Patients With Type 2 Diabetes
  • Leveraging SGLT2 Inhibitors in T2D and HF: A Shared Approach
  • Summary
  • Question and Answer Session

Jennifer B. Green, MD
Professor of Medicine
Division of Endocrinology
Department of Medicine
Duke University Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Mikhail Kosiborod, MD
Professor of Medicine
Kansas City School of Medicine
University of Missouri
Consulting Cardiologist Division of Cardiovascular Research
Department of Cardiology
Saint Luke's Mid America Heart Institute
Kansas City, Missouri

STATEMENT OF INDEPENDENCE

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

DISCLOSURE POLICY

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:

  • Jennifer B. Green, MD: Consultant, AstraZeneca, Boehringer Ingelheim/Lilly, Hawthorne Effect/Omada, Novo Nordisk, Pfizer, Sanofi/Lexicon; Research Support, AstraZeneca, Boehinger Ingelheim/Lilly, Roche, Sanofi/Lexicon
  • Mikhail N. Kosiborod, MD: Consultant, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Lilly, Merck; Research Support, AstraZeneca, Bayer, Boehringer Ingelheim

The following SPC member who planned and reviewed content for this activity reported relevant financial relationships:

  • Andjela T. Drincic, MD: Advisory Board Member: Corcept Therapeutics

The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

Disclosure information for presenters is included in their individual recorded presentations.

The following SPC members reported no relevant financial relationships:

  • Howard S. Blank, MD; Beret Ann Casey, MD; Lediya Cheru, MD; Marcelo Correia, MD, PhD; Angela M. Leung, MD; Kelly Lauter Roszko, MD, PhD; Virginia D. Sarapura, MD; Soleymani Taraneh, MD; Savitha Subramanian, MD

The ES and CCO staff involved in the development of this CME activity reported no relevant financial relationships.

DISCLAIMERS

USE OF PROFESSIONAL JUDGMENT:

The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:

When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.

POLICY ON UNLABELED/OFF-LABEL USE

The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

PRIVACY AND CONFIDENTIALITY STATEMENT

The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

ACKNOWLEDGMENT OF COMMERCIAL SUPPORT

This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company. Provided by the Endocrine Society in collaboration with Clinical Care Options

Certified for up to 1.00 AMA PRA Category 1 Credit™

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA PRA Category 1 Credit:

The Endocrine Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Participants must complete the activity evaluation by June 30, 2022. For questions about content or obtaining CME credit, please contact info@education.org. 

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Available Credit

  • 1.00 AMA PRA Category 1 Credits
  • 1.00 CME Certificate of Participation